Sign up to save your podcasts
Or
Share Antiplatelets After ASCVD: Less Autopilot, More Judgment đź§
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Antiplatelets After ASCVD: Less Autopilot, More Judgment đź§
🩸 Antiplatelet therapy is no longer "aspirin for all" or "DAPT by habit." The 2026 ACC Scientific Statement reframes care around precision: ischemic risk, bleeding risk, PCI/ACS context, PAD or stroke phenotype, surgery, anticoagulation, and adherence. The modern message: choose the right agent, right intensity, and right duration—then reassess. Platelets may be small, but the decisions are not. ⚖️🔬
Source: 2026 ACC Scientific Statement on antiplatelet therapy.
View all episodes
By Dr RR Baliga, MD, MBA
5
66 ratings
🩸 Antiplatelet therapy is no longer "aspirin for all" or "DAPT by habit." The 2026 ACC Scientific Statement reframes care around precision: ischemic risk, bleeding risk, PCI/ACS context, PAD or stroke phenotype, surgery, anticoagulation, and adherence. The modern message: choose the right agent, right intensity, and right duration—then reassess. Platelets may be small, but the decisions are not. ⚖️🔬
Source: 2026 ACC Scientific Statement on antiplatelet therapy.
More shows like Dr RR Baliga's "Got Knowledge Doc" Podkast
View all
This Week in Cardiology
895 Listeners
The Curbsiders Internal Medicine Podcast
3,360 Listeners
The Mel Robbins Podcast
19,524 Listeners